World J Surg Oncol. 2025 Nov 11;23(1):429. doi: 10.1186/s12957-025-04080-x.
ABSTRACT
OBJECTIVE: Retrospective analysis of the safety and efficacy of radical right hemicolectomy combined with hyperthermic intraperitoneal chemotherapy in the treatment of appendiceal mucinous tumors.
METHOD: Data were extracted from inpatient and outpatient medical records. Using R software (version 4.3.2), we collected all cases of appendiceal mucinous tumors treated with HIPEC at Jingzhou Hospital Affiliated to Yangtze University from February 2015 to February 2022 for statistical analysis and visualization. Survival analysis was performed using the ‘survival’ package, survival curves were plotted with ‘survminer’, and boxplots and percentage bar charts were generated using ‘ggplot2’.
RESULT: This study included 61 patients with appendiceal mucinous tumors, of whom 31 received postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and 30 did not. At 2 years, recurrence occurred in 12.9% of the HIPEC group versus 46.7% of the control group (P = 0.004). The hazard ratio (HR) for recurrence-free survival (RFS) was 0.21 (95% CI: 0.07-0.63; P = 0.002). Overall survival (OS) at 2 years was 93.5% with HIPEC and 80.0% without, a difference that did not reach statistical significance (P = 0.147). Postoperative complication rates and baseline characteristics were comparable between groups.
CONCLUSION: Our findings demonstrate that radical right hemicolectomy combined with HIPEC significantly reduces postoperative recurrence rates in AMN patients while showing a non-significant trend toward improved overall survival.
PMID:41219906 | DOI:10.1186/s12957-025-04080-x
